Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
98.55
-3.31 (-3.25%)
Streaming Delayed Price
Updated: 12:29 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Rhythm Pharmaceuticals CFO Sells 42,120 Shares
↗
July 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
July 12, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
July 10, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
↗
June 05, 2025
Via
Benzinga
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells
↗
July 10, 2025
Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.
Via
Stocktwits
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
July 09, 2025
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise
↗
July 09, 2025
Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 09, 2025
Via
Benzinga
These stocks are moving in today's session
↗
July 09, 2025
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
↗
July 09, 2025
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.
Via
Stocktwits
Topics
Government
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity
↗
July 09, 2025
Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat obesity.
Via
Investor's Business Daily
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
↗
July 09, 2025
Via
Benzinga
Which stocks are gapping on Wednesday?
↗
July 09, 2025
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
July 09, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
July 08, 2025
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity
July 08, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
8 Analysts Have This To Say About Rhythm Pharmaceuticals
↗
June 26, 2025
Via
Benzinga
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
June 25, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria
↗
May 22, 2025
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.
Via
Chartmill
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
May 14, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
↗
May 07, 2025
Via
Benzinga
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
May 07, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 06, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
April 23, 2025
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
↗
April 13, 2025
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
Via
Benzinga
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
↗
April 08, 2025
Via
Benzinga
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
April 08, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
